

The negative haemodynamic effects of untreated moderate-to-severe aortic regurgitation (AR) could be severe, while less severe AR might be less cumbersome.² Our results clearly demonstrated that a concomitant AoV procedure was an independent risk predictor for all-cause mortality post-LVAD implantation. Patients with less severe AR who underwent an AoV procedure had a worse survival compared to those without an AoV procedure, while only in patients with moderate-to-severe AR no survival differences were observed. These results suggest that the positive effects of resolving AR overcome the incremental risk associated with a concomitant AoV procedure, while this was not the case in patients with less severe AR.

We agree that an aneurysm of the ascending aorta could induce or exacerbate pre-existing AR. However, albeit the long-term LVAD support might induce a progressive ascending aorta dilatation, data regarding this phenomenon are still very scarce.³ Unfortunately, no data regarding the development of ascending aorta aneurysms were available in the IMACS Registry.

In patients with reduced right ventricular (RV) function post-LVAD implantation, long-lasting AR increases the risk for all-cause mortality. Additionally, it has been shown that long-lasting AR has a negative effect on RV function. However, considering all LVAD patients, AR does not affect the overall survival, which is in line with our results. Specific sub-analysis in patients with a compromised RV function could give some answers, but this is not yet done.

The largest survival gap between patients with and without a concomitant AoV procedure occurs in the first 3 months post-LVAD implantation. We agree that the most likely explanation is the prolonged surgical time with detrimental effects on RV function and increased risk of perioperative morbidity and mortality.⁴ Once the acute phase is past, there will be a new haemodynamic and clinical equilibrium which will be much better tolerated.

We agree that Impella support can induce AoV damage leading to more unplanned AoV procedures.⁵ However, the preoperative use of Impella support was not available in the IMACS Registry.

During the first 3 months, AoV repair patients died more often from a major infection compared to the AoV replacement group. Patients with an AoV repair have a prolonged surgical time and spend more time in the intensive care unit ward, which is associated with an increased risk for sepsis. An AoV replacement procedure is associated

doi:10.1002/ejhf.2114
Online publish-ahead-of-print 16 March 2021

Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'

We read with interest the letter from the colleagues Loardi and Zanobini and would like to thank them for their useful comments on our recently published paper on the effects of concomitant aortic valve (AoV) procedures during left ventricular assist device (LVAD) implantation in patients enrolled in the ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry.¹

with a higher risk for multi-system organ failure and other procedure-related complications. This could contribute that patients with an AoV replacement died less often from severe infection compared to AoV repair patients. However, more research into the potential difference in severe infections between the two procedures is needed to provide a more definite answer.

**Jesse F. Veenis¹, Jasper J. Brugts¹,
Yunus C. Yalcin^{1,2}, and Kadir Caliskan^{1*}**

¹Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; and ²Department of Cardiothoracic Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

*Email: k.caliskan@erasmusmc.nl

References

1. Veenis JF, Yalcin YC, Brugts JJ, Constantinescu AA, Manintveld OC, Bekkers JA, Bogers A, Caliskan K. Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry analysis. *Eur J Heart Fail* 2020;**22**:1878–1887.
2. Truby LK, Garan AR, Givens RC, Wayda B, Takeda K, Yuzefpolskaya M, Colombo PC, Naka Y, Takayama H, Topkara VK. Aortic insufficiency during contemporary left ventricular assist device support: analysis of the INTERMACS registry. *JACC Heart Fail* 2018;**6**:951–960.
3. Fine NM, Park SJ, Stulak JM, Topilsky Y, Daly RC, Joyce LD, Pereira NL, Schirger JA, Edwards BS, Lin G, Kushwaha SS. Proximal thoracic aorta dimensions after continuous-flow left ventricular assist device implantation: longitudinal changes and relation to aortic valve insufficiency. *J Heart Lung Transplant* 2016;**35**:423–432.
4. Soliman Oll, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T, Gummert JF, de By T, Bogers A, Zijlstra F, Mohacsi P, Caliskan K; EUROMACS Investigators. Derivation and validation of a novel right-sided heart failure model after implantation of continuous flow left ventricular assist devices: the EUROMACS (European Registry for Patients with Mechanical Circulatory Support) right-sided heart failure risk score. *Circulation* 2018;**137**:891–906.
5. Rao SD, Johnson B, Olia SE, Wald J, Medina V, Rame JE, Mazurek JA, Goldberg LR, Atluri P, Bermudez C, Acker M, Birati EY. Treatment with impella increases the risk of de novo aortic insufficiency post left ventricular assist device implant. *J Card Fail* 2020;**26**:870–875.